Xencor has received a milestone payment under a technology license agreement with Boehringer Ingelheim, triggered by a regulatory submission to begin Phase I trials of a novel monoclonal antibody that was optimized using Xencor’s XmAb antibody engineering technology. This is the second XmAb candidate entering clinical trials under the agreement. The two companies entered a license agreement in 2007 to use Xencor’s XmAb antibody-dependent cell cytotoxicity (ADCC) technology to enhance the potenc...